A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the efficacy of TLN-4601 in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month progression free survival from date of initial infusion of TLN-4601 (Day 1, Cycle 1).
6-month progression free survival from date of initial infusion of TLN-4601 (Day 1, Cycle 1)
No
Warren Mason, MD
Principal Investigator
The Pencer Brain Tumor Center, Princess Margaret Hospital, Toronto
United States: Food and Drug Administration
TLN-4601-201
NCT00730262
August 2008
June 2010
Name | Location |
---|---|
Duke University | Durham, North Carolina 27710 |
Sloan-Kettering Institute for Cancer Research | New York, New York 10021 |